Tumor-associated mutation-derived peptide antigen

Tumor-associated mutation-derived peptide antigens are short peptide fragments generated from tumor cell proteins that harbor mutations specific to cancer cells, known as neoantigens or mutation-derived antigens.[1][3][6] These peptides are produced intracellularly and presented on the tumor cell surface by major histocompatibility complex (MHC) molecules. When recognized by T cells, especially cytotoxic T lymphocytes, these peptides can trigger an immune response specifically targeting cancer cells while sparing most normal tissues.[1][3] Because these antigens are unique to tumor cells (unlike many typical tumor-associated antigens also seen in normal tissue), they are attractive targets for immunotherapies, including personalized peptide vaccines, adoptive cell therapy using tumor-infiltrating lymphocytes or TCR-engineered T cells, and as biomarkers of treatment response or immune monitoring.[1][3] Their specificity for cancer and ability to induce a robust T cell response have made them central to the development of modern cancer immunotherapies. Not all mutation-derived peptides are immunogenic, and the identification and targeting of relevant antigens is a focus of ongoing clinical research.[1][3][4]

Other names

Tumor-associated antigen (if the peptide is derived from a non-mutated but aberrantly expressed protein)Tumor-specific antigen (if derived from cancer-specific mutation)Neoantigen (if derived specifically from somatic tumor mutations)Mutation-derived peptide antigen

Immune activation via T cell recognition of presented peptide-MHC complexes; Induction of cytotoxic T lymphocyte-mediated tumor cell killing